|Type||Single-chain variable fragment|
|Chemical and physical data|
|Molar mass||69.6 kg/mol g·mol−1|
|(what is this?)|
Oportuzumab monatox (proposed INN, trade name Vicinium) is an antineoplastic. Chemically, oportuzumab it is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). The drug is produced by Viventia Bio, a Canadian company with laboratories in Winnipeg, Canada and headquarters in Philadelphia, Pennsylvania, USA. Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name).
Vicinium has been evaluated in phase I and II clinical trials in patients with non-muscle invasive bladder cancer. In these studies, treatment was associated with clinical benefit.
- International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- Phase I/II study of vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I results D. Fitsialos, S. Seitz, E. Wiecek, M. Rasamoelisolo, J. Entwistle, M. Jewett, G. C. MacDonald and N. Glover. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 4580
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|